

## Solomon Islands Support for Measles-Rubella Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Solomon Islands				
<b>2. Grant number:</b> 1820-SLB-18b-X / 18-SLB-08k-Y /				
<b>3. Date of Decision Letter:</b> 19 May 2017				
<b>4. Date of the Partnership Framework Agreement:</b> 29 April 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Measles-Rubella Second Dose routine				
<b>6. Vaccine type:</b> Measles-Rubella				
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED				
<b>8. Programme duration<sup>1</sup>:</b> 2018 - 2020				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)				
	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	US\$11,500	US\$9,000	US\$7,000	US\$27,500
<b>10. Vaccine introduction grant (in US\$):</b> 100,000. Payable up to six months before vaccine introduction.				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup>				
Type of supplies to be purchased with Gavi funds in each year				2018
Number of Measles-Rubella vaccines doses				17,800
Annual Amounts (US\$)				US\$11,500
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>13. Self-procurement:</b> Not applicable				

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Co-financing obligations:** Reference code: 1820-SLB-18b-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	14,400	18,400	23,100
Number of AD syringes	10,800		
Number of re-constitution syringes	1,600		
Number of safety boxes	150		
Value of vaccine doses (US\$)	US\$8,776		
Total co-financing payments (US\$) (including freight)	US\$10,000	US\$12,500	US\$15,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:

Not applicable

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

19 May 2017